Andrew Ashe - Jan 8, 2025 Form 4 Insider Report for Verve Therapeutics, Inc. (VERV)

Role
President, Chief Operating Officer and General Counsel
Signature
/s/ Andrew Ashe
Stock symbol
VERV
Transactions as of
Jan 8, 2025
Transactions value $
$0
Form type
4
Date filed
1/10/2025, 09:00 AM
Previous filing
May 15, 2024
Next filing
Apr 3, 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VERV Stock Option (right to buy) Award $0 +225K $0.00 225K Jan 8, 2025 Common Stock 225K $6.01 Direct F1
transaction VERV Restricted Stock Units Award $0 +40K $0.00 40K Jan 8, 2025 Common Stock 40K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option was granted on January 8, 2025. 25% of the shares underlying the option will vest on January 8, 2026, and the remainder are scheduled to vest in equal monthly installments thereafter until January 8, 2029.
F2 Each restricted stock unit represents a contingent right to receive one share of common stock.
F3 On January 8, 2025, the reporting person was granted restricted stock units, vesting in three equal annual installments, beginning on April 1, 2026, and the remaining two installments vesting on April 1, 2027 and April 1, 2028.

Remarks:

President, Chief Operating Officer and General Counsel